Simplex Trading’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.11K | Buy |
+700
| New | +$1.18K | ﹤0.01% | 8577 |
|
|
2025
Q4 | – | Sell |
-31,000
| Closed | -$52K | – | 9372 |
|
|
2025
Q3 | $52K | Sell |
31,000
-67,200
| -68% | -$79.5K | ﹤0.01% | 6419 |
|
|
2025
Q2 | $89K | Sell |
98,200
-8,200
| -8% | -$4.86K | ﹤0.01% | 5353 |
|
|
2025
Q1 | $48K | Buy |
+106,400
| New | +$62.4K | ﹤0.01% | 5806 |
|
|
2024
Q3 | – | Sell |
-1,100
| Closed | -$1K | – | 9067 |
|
|
2024
Q2 | $1K | Buy |
+1,100
| New | +$1.22K | ﹤0.01% | 8485 |
|
|
2023
Q2 | – | Sell |
-28,600
| Closed | -$42K | – | 9498 |
|
|
2023
Q1 | $42K | Sell |
28,600
-9,000
| -24% | -$12.6K | ﹤0.01% | 6119 |
|
|
2022
Q4 | $43K | Buy |
37,600
+13,200
| +54% | +$16.6K | ﹤0.01% | 6053 |
|
|
2022
Q3 | $27K | Buy |
24,400
+15,800
| +184% | +$23.2K | ﹤0.01% | 7188 |
|
|
2022
Q2 | $13K | Buy |
8,600
+3,700
| +76% | +$4.88K | ﹤0.01% | 8048 |
|
|
2022
Q1 | $7K | Sell |
4,900
-76,700
| -94% | -$119K | ﹤0.01% | 9176 |
|
|
2021
Q4 | $199K | Buy |
81,600
+58,200
| +249% | +$136K | ﹤0.01% | 5208 |
|
|
2021
Q3 | $66K | Buy |
23,400
+100
| +0.4% | +$257 | ﹤0.01% | 7166 |
|
|
2021
Q2 | $66K | Buy |
23,300
+23,177
| +18,843% | +$60K | ﹤0.01% | 7289 |
|
|
2021
Q1 | $28K | Sell |
123
-1,017
| -89% | -$2.44K | ﹤0.01% | 7184 |
|
|
2020
Q4 | $200K | Buy |
1,140
+1,042
| +1,063% | +$1.46K | ﹤0.01% | 4601 |
|
|
2020
Q3 | $9K | Sell |
98
-114
| -54% | -$101 | ﹤0.01% | 6846 |
|
|
2020
Q2 | $18K | Sell |
212
-321
| -60% | -$283 | ﹤0.01% | 6297 |
|
|
2020
Q1 | $44K | Buy |
+533
| New | +$531 | ﹤0.01% | 5260 |
|
|
2019
Q4 | – | Sell |
-18
| Closed | -$1K | – | 7640 |
|
|
2019
Q3 | $1K | Buy |
+18
| New | +$19 | ﹤0.01% | 7045 |
|
|
2019
Q2 | – | Sell |
-23
| Closed | -$2K | – | 7471 |
|
|
2019
Q1 | $2K | Sell |
23
-10
| -30% | -$12 | ﹤0.01% | 6794 |
|
|
2018
Q4 | $2K | Sell |
33
-56
| -63% | -$86 | ﹤0.01% | 6575 |
|
|
2018
Q3 | $18K | Buy |
89
+59
| +197% | +$124 | ﹤0.01% | 6039 |
|
|
2018
Q2 | $5K | Buy |
+30
| New | +$60 | ﹤0.01% | 6709 |
|
|
2017
Q4 | – | Sell |
-58
| Closed | -$1K | – | 6339 |
|
|
2017
Q3 | $1K | Buy |
+58
| New | +$144 | ﹤0.01% | 5471 |
|
|
2017
Q1 | – | Sell |
-79
| Closed | -$1K | – | 6469 |
|
|
2016
Q4 | $1K | Sell |
79
-134
| -63% | -$411 | ﹤0.01% | 5426 |
|
|
2016
Q3 | $7K | Buy |
+213
| New | +$588 | ﹤0.01% | 3949 |
|
|
2016
Q1 | – | Sell |
-58
| Closed | -$1K | – | 5923 |
|
|
2015
Q4 | $1K | Buy |
58
+2
| +4% | +$6 | ﹤0.01% | 4898 |
|
|
2015
Q3 | $3K | Buy |
+56
| New | +$145 | ﹤0.01% | 4364 |
|
|
2015
Q2 | – | Sell |
-79
| Closed | -$15K | – | 5526 |
|
|
2015
Q1 | $15K | Buy |
+79
| New | +$273 | ﹤0.01% | 2552 |
|
Other funds holding LCTX
BC
VCM
DC
RA
AC
Simplex Trading's LCTX Position: Q1 2026 in Review
Simplex Trading opened a new position in Lineage Cell Therapeutics (LCTX) in Q1 2026: 9,698 shares worth $15.3K. The stake represents ﹤0.01% of the portfolio and ranks #6977 among its holdings. This is a return to the name: Simplex Trading previously reported a position in LCTX as recently as Q3 2025.
Simplex Trading first reported a position in LCTX in Q2 2015 and has held it in 31 quarters since. The position peaked at $168K in Q1 2021. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.
- Simplex Trading held 9,698 shares of Lineage Cell Therapeutics worth $15.3K as of Q1 2026.
- Lineage Cell Therapeutics was a new Simplex Trading position in Q1 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6977 holding.
- Simplex Trading first reported a position in Lineage Cell Therapeutics in Q2 2015 and has held it in 31 quarters since.
- Simplex Trading's Lineage Cell Therapeutics position peaked at $168K in Q1 2021.
- 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.